NCT00895739 2013-08-12
Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure
National Cancer Institute (NCI)
Phase 2 Unknown
Clinical Trials
7 trialsNCT00720447 2013-08-02
Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00907036 2013-08-02
Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00908180 2013-08-02
Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00337519 2009-01-29
Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia
Charite University, Berlin, Germany
Phase 2 Unknown
NCT00800943 2008-12-03
CRC005
Chronic Lymphocytic Leukemia Research Consortium
Phase 2 Unknown
NCT00157274 2007-04-03
Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome
Latin American Cooperative Onco-Haematology Group - Peru
Phase 2 Unknown